Sun Pharma slips nearly 4% as USFDA issues import alert on Halol facility

For the year ended March 31, 2022, supplies to the US market from the Halol facility accounted for approximately 3 per cent of the company's consolidated revenues.

Shares of Sun Pharmaceutical Industries slipped 3.5 per cent to Rs 981.50 on the BSE in Thursday’s intra-day after the company said that the US health regulator has put its manufacturing facility at Halol under import alert.

The company has received a communication from the US Food and Drug Administration (USFDA) stating that the facility has been listed under Import Alert, Sun Pharma said in an exchange filing. USFDA had inspected the company’s Halol (Gujarat) facility from April 26 to May 9, 2022.

The import alert implies inter alia, that all future shipments of products manufactured at this